Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapySolid TumorsProtocol groupGastroenterologic OncologyradiotherapyDiseasePancreatic CancerSubgroupICD10C25.-MeSHPancreatic NeoplasmsSequenceGEMC1000/CAPE830, Pancreatic Ca (PID1980) -|- CAPE830/Radiation (PID1968)ChemotherapyChemo-substanceCapecitabineGemcitabineChemo-substanceCapecitabineGemcitabineChemo-substanceCapecitabineGemcitabineChemo-substanceCapecitabineGemcitabineNo. Substances12 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionGranisetronSupportive substanceBalanced Crystalloid SolutionGranisetronSupportive substanceBalanced Crystalloid SolutionGranisetronSupportive substanceBalanced Crystalloid SolutionGranisetronNo. Substances12Protocol classificationTherapy classificationalternativeIntensityStandard doseTherapy indicationFirst lineTherapy phaseneoadjuvantTherapy intentioncurativepalliativeRisksAnemia Hb below 8g/dlAnorexiaEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)FatigueFebrile NeutropeniaHypokalemiaNeutropeniaThrombocytopenia below 50 000/µl only studiesPublicationAuthorHurt CLoehrer PDiseaselokal fortgeschrittenes, nicht-resezierbares Pankreas-Ca, ECOG 0-1nicht resezierbares / borderline Adenokarzinom des Pankreas, neoadjuvant, Erstlinie, ECOG 0-2OriginCancer Center, Indiana University, IndianapolisWales Cancer Trials Unit, College of Biomedical and Life Sciences, Cardiff University, United Kingdom, Scalop trialProtocols in Revision 3 protocols foundProtocols under revision.Capecitabine 830 / Radiation, Pancreatic Cancer (PID1968 V2.0)Gemcitabine 1000 / Capecitabine 830, Pancreatic Cancer (PID1980 V1.2)Gemcitabine 600 / Radiation, Pancreatic Cancer, Neoadjuvant (PID1161 V1.1)
